Robert F. Siliciano

Q: What Schools Are Affiliated With Robert F. Siliciano

Robert F. Siliciano is affiliated with the following schools: Princeton University, Johns Hopkins University, University of California, San Francisco, Massachusetts General Hospital

Robert F. Siliciano's AcademicInfluence.com Rankings

Robert F. Siliciano

Biology

#1663

World Rank

#2722

Historical Rank

#808

USA Rank

Biochemistry

#893

World Rank

#1001

Historical Rank

#234

USA Rank

biology Degrees

Robert F. Siliciano

Philosophy

#5209

World Rank

#7951

Historical Rank

#1394

USA Rank

Logic

#2526

World Rank

#3531

Historical Rank

#594

USA Rank

philosophy Degrees

Download Badge

Biology
Philosophy

Robert F. Siliciano's Degrees

Doctorate Medicine University of California, San Francisco
PhD Biochemistry University of California, San Francisco

Why Is Robert F. Siliciano Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Robert F. Siliciano is a professor of medicine at the Johns Hopkins University School of Medicine and an investigator with the Howard Hughes Medical Institute. Siliciano has a joint appointment in the Department of Molecular Biology and Genetics at Johns Hopkins. Siliciano researches the mechanisms by which the human immunodeficiency virus remains latent in the human body.

(See a Problem?)

Robert F. Siliciano's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. (1997) (2876)
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy (1999) (2106)
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection (1997) (2041)
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells (2003) (1484)
Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure (2013) (1151)
In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency (1995) (723)
Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. (2012) (702)
The challenge of viral reservoirs in HIV-1 infection. (2002) (626)
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. (2000) (540)
Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies (2013) (537)
Defective proviruses rapidly accumulate during acute HIV-1 infection (2016) (534)
Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations (2015) (464)
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy (2009) (443)
Novel ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo (2014) (434)
Redefining the viral reservoirs that prevent HIV-1 eradication. (2012) (426)
A soluble CD4 protein selectively inhibits HIV replication and syncytium formation (1988) (406)
Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells (2006) (403)
Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. (2005) (389)
HIV-1 Integration Landscape during Latent and Active Infection (2015) (375)
Control of HIV despite the discontinuation of antiretroviral therapy. (1999) (359)
An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients (2013) (358)
Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: Effect of HIV sequence variation and a mechanism for CD4+ cell depletion (1988) (344)
Resting CD4+ T Cells from Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals Carry Integrated HIV-1 Genomes within Actively Transcribed Host Genes (2004) (336)
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. (2015) (328)
Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs (2008) (324)
Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics (2017) (294)
Viral Dynamics in HIV-1 Infection (1998) (293)
The HBV drug entecavir - effects on HIV-1 replication and resistance. (2007) (286)
Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein (1985) (286)
A novel quantitative approach for measuring the reservoir of latent HIV-1 proviruses (2019) (279)
Maintenance of viral suppression in HIV-1–infected HLA-B*57+ elite suppressors despite CTL escape mutations (2006) (278)
Isolation and Characterization of Replication-Competent Human Immunodeficiency Virus Type 1 from a Subset of Elite Suppressors (2006) (276)
Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient (2013) (275)
The multifactorial nature of HIV-1 latency. (2004) (260)
Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 (2014) (259)
Molecular Characterization of Preintegration Latency in Human Immunodeficiency Virus Type 1 Infection (2002) (256)
Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. (2009) (255)
Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. (2005) (254)
Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape. (2017) (238)
Targeting the Latent Reservoir for HIV‐1 (2018) (236)
Experimental approaches to the study of HIV-1 latency (2007) (234)
HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. (2001) (229)
Rapid Quantification of the Latent Reservoir for HIV-1 Using a Viral Outgrowth Assay (2013) (227)
Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. (2004) (227)
Antiretroviral resistance during successful therapy of HIV type 1 infection. (2000) (226)
HIV reservoirs: what, where and how to target them (2015) (220)
Kinetics of Human Immunodeficiency Virus Type 1 Decay following Entry into Resting CD4+ T Cells (2005) (212)
Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. (2008) (206)
Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. (2008) (203)
BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism (2013) (202)
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. (1998) (201)
Screening for noise in gene expression identifies drug synergies (2014) (197)
Nuclear Retention of Multiply Spliced HIV-1 RNA in Resting CD4+ T Cells (2006) (196)
Towards an HIV-1 cure: measuring the latent reservoir. (2015) (196)
Targeting of HIV-1 Antigens for Rapid Intracellular Degradation Enhances Cytotoxic T Lymphocyte (CTL) Recognition and the Induction of De Novo CTL Responses In Vivo After Immunization (1997) (194)
Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC. (1995) (191)
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. (2007) (190)
Analysis of Human Immunodeficiency Virus Type 1 Gene Expression in Latently Infected Resting CD4+ T Lymphocytes In Vivo (2003) (189)
HIV latency. (2011) (186)
Disulfiram Reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4+ T Cell Model without Inducing Global T Cell Activation (2011) (183)
Novel Single-Cell-Level Phenotypic Assay for Residual Drug Susceptibility and Reduced Replication Capacity of Drug-Resistant Human Immunodeficiency Virus Type 1 (2004) (182)
A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. (2000) (182)
Intrinsic Stability of Episomal Circles Formed during Human Immunodeficiency Virus Type 1 Replication (2002) (179)
Latency in Human Immunodeficiency Virus Type 1 Infection: No Easy Answers (2003) (177)
Chronic CD4+ T-Cell Activation and Depletion in Human Immunodeficiency Virus Type 1 Infection: Type I Interferon-Mediated Disruption of T-Cell Dynamics (2007) (176)
Antiretroviral dynamics determines HIV evolution and predicts therapy outcome (2012) (175)
G→A Hypermutation in Protease and Reverse Transcriptase Regions of Human Immunodeficiency Virus Type 1 Residing in Resting CD4+ T Cells In Vivo (2005) (173)
Neutralizing Antibodies Do Not Mediate Suppression of Human Immunodeficiency Virus Type 1 in Elite Suppressors or Selection of Plasma Virus Variants in Patients on Highly Active Antiretroviral Therapy (2006) (172)
HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study (2017) (171)
A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. (2014) (170)
Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane (2018) (169)
Outwitting Evolution: Fighting Drug-Resistant TB, Malaria, and HIV (2012) (169)
Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. (2000) (167)
Characterization of Chemokine Receptor Utilization of Viruses in the Latent Reservoir for Human Immunodeficiency Virus Type 1 (2000) (156)
A Simian Immunodeficiency Virus-Infected Macaque Model To Study Viral Reservoirs That Persist during Highly Active Antiretroviral Therapy (2009) (151)
The mTOR Complex Controls HIV Latency. (2016) (148)
Analysis of Human Immunodeficiency Virus Type 1 Transcriptional Elongation in Resting CD4+ T Cells In Vivo (2004) (148)
A Quantitative Basis for Antiretroviral Therapy for HIV-1 Infection (2012) (147)
Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine. (1990) (145)
Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. (2013) (142)
Preservation of FoxP3+ Regulatory T Cells in the Peripheral Blood of Human Immunodeficiency Virus Type 1-Infected Elite Suppressors Correlates with Low CD4+ T-Cell Activation (2008) (141)
A long-term latent reservoir for HIV-1: discovery and clinical implications. (2004) (137)
Targeting HIV latency: pharmacologic strategies toward eradication. (2013) (137)
Persistence of Wild-Type Virus and Lack of Temporal Structure in the Latent Reservoir for Human Immunodeficiency Virus Type 1 in Pediatric Patients with Extensive Antiretroviral Exposure (2002) (135)
Human immunodeficiency virus type 1 envelope protein endocytosis mediated by a highly conserved intrinsic internalization signal in the cytoplasmic domain of gp41 is suppressed in the presence of the Pr55gag precursor protein (1996) (133)
Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells (2018) (131)
Analysis of Human Immunodeficiency Virus Type 1 Viremia and Provirus in Resting CD4+ T Cells Reveals a Novel Source of Residual Viremia in Patients on Antiretroviral Therapy (2009) (130)
Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle (2008) (130)
The Latent Reservoir for HIV-1: How Immunologic Memory and Clonal Expansion Contribute to HIV-1 Persistence (2016) (124)
Control of HIV-1 in Elite Suppressors despite Ongoing Replication and Evolution in Plasma Virus (2010) (122)
Resting CD4+ T Lymphocytes but Not Thymocytes Provide a Latent Viral Reservoir in a Simian Immunodeficiency Virus-Macaca nemestrina Model of Human Immunodeficiency Virus Type 1-Infected Patients on Highly Active Antiretroviral Therapy (2003) (121)
HIV-1 viral load blips are of limited clinical significance. (2006) (120)
Influence of Host Gene Transcription Level and Orientation on HIV-1 Latency in a Primary-Cell Model (2011) (119)
Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. (2006) (119)
Transcriptional Reprogramming during Effector‐to‐Memory Transition Renders CD4+ T Cells Permissive for Latent HIV‐1 Infection (2017) (119)
Designing and Interpreting Limiting Dilution Assays: General Principles and Applications to the Latent Reservoir for Human Immunodeficiency Virus-1 (2015) (117)
Distinct viral reservoirs in individuals with spontaneous control of HIV-1 (2020) (116)
Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells. (1995) (114)
Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine (1993) (114)
HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy. (2012) (114)
The Human Immunodeficiency Virus Type 1gag Gene Encodes an Internal Ribosome Entry Site (2001) (111)
Role of interaction of CD2 molecules with lymphocyte function-associated antigen 3 in T-cell recognition of nominal antigen. (1990) (111)
Elite Suppressor–Derived HIV-1 Envelope Glycoproteins Exhibit Reduced Entry Efficiency and Kinetics (2009) (111)
Continued Production of Drug-Sensitive Human Immunodeficiency Virus Type 1 in Children on Combination Antiretroviral Therapy Who Have Undetectable Viral Loads (2004) (110)
Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques (2016) (107)
Transmission of Human Immunodeficiency Virus Type 1 from a Patient Who Developed AIDS to an Elite Suppressor (2008) (104)
Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. (1995) (103)
HIV latency and integration site placement in five cell-based models (2013) (101)
CD4+ and CD8+ T Cell Activation Are Associated with HIV DNA in Resting CD4+ T Cells (2014) (96)
Transporter-independent processing of HIV-1 envelope protein for recognition by CD8+ T cells (1993) (95)
Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. (1999) (94)
The Antiherpetic Drug Acyclovir Inhibits HIV Replication and Selects the V75I Reverse Transcriptase Multidrug Resistance Mutation* (2008) (92)
Comparative clonal analysis of human immunodeficiency virus type 1 (HIV- 1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines (1992) (91)
Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy. (2020) (91)
Developing strategies for HIV-1 eradication. (2012) (90)
A mechanistic theory to explain the efficacy of antiretroviral therapy (2014) (90)
Dose–response curve slope is a missing dimension in the analysis of HIV-1 drug resistance (2011) (89)
The human NTT gene: identification of a novel 17-kb noncoding nuclear RNA expressed in activated CD4+ T cells. (1997) (88)
Role of APOBEC3G/F-Mediated Hypermutation in the Control of Human Immunodeficiency Virus Type 1 in Elite Suppressors (2007) (88)
A soluble, single-chain T-cell receptor fragment endowed with antigen-combining properties. (1991) (87)
Direct Priming and Cross-Priming Contribute Differentially to the Induction of CD8+ CTL Following Exposure to Vaccinia Virus Via Different Routes1 (2002) (86)
An epitope-selective, transporter associated with antigen presentation (TAP)-1/2-independent pathway and a more general TAP-1/2-dependent antigen-processing pathway allow recognition of the HIV-1 envelope glycoprotein by CD8+ CTL. (1995) (86)
Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV (2016) (86)
Differential susceptibility of naive and memory CD4+ T cells to the cytopathic effects of infection with human immunodeficiency virus type 1 strain LAI (1997) (86)
Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. (2004) (85)
Therapeutic Vaccination with Simian Immunodeficiency Virus (SIV)-DNA+IL-12 or IL-15 Induces Distinct CD8 Memory Subsets in SIV-Infected Macaques1 (2008) (85)
A Novel PCR Assay for Quantification of HIV-1 RNA (2013) (84)
Severe Depletion of CD4+ CD25+ Regulatory T Cells from the Intestinal Lamina Propria but Not Peripheral Blood or Lymph Nodes during Acute Simian Immunodeficiency Virus Infection (2007) (83)
From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication. (2013) (83)
Measuring the Frequency of Latent HIV-1 in Resting CD4⁺ T Cells Using a Limiting Dilution Coculture Assay. (2016) (82)
Limits on Replenishment of the Resting CD4+ T Cell Reservoir for HIV in Patients on HAART (2007) (82)
Nuclear landscape of HIV-1 infection and integration (2016) (81)
HIV‐1 latent reservoir size and diversity are stable following brief treatment interruption (2018) (80)
Role of Natural Killer Cells in a Cohort of Elite Suppressors: Low Frequency of the Protective KIR3DS1 Allele and Limited Inhibition of Human Immunodeficiency Virus Type 1 Replication In Vitro (2009) (79)
Progress Toward HIV Eradication: Case Reports, Current Efforts, and the Challenges Associated with Cure. (2016) (77)
Cutting edge: induction of enhanced CTL-dependent protective immunity in vivo by N-end rule targeting of a model tumor antigen. (1999) (74)
Recommendations for measuring HIV reservoir size in cure-directed clinical trials (2020) (74)
The interaction of nominal antigen with T cell antigen receptors. I. Specific binding of multivalent nominal antigen to cytolytic T cell clones. (1985) (74)
HIV-1 eradication strategies: design and assessment (2013) (72)
Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1. (2014) (72)
Local Sequence Targeting in the AID/APOBEC Family Differentially Impacts Retroviral Restriction and Antibody Diversification* (2010) (72)
No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. (2010) (71)
The Remarkable Stability of the Latent Reservoir for HIV-1 in Resting Memory CD4+ T Cells. (2015) (68)
Direct evidence for the existence of nominal antigen binding sites on T cell surface Ti α-β heterodimers of MHC-restricted T cell clones (1986) (67)
Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells. (2010) (67)
Uracil DNA glycosylase initiates degradation of HIV-1 cDNA containing misincorporated dUTP and prevents viral integration (2013) (67)
A Critical Subset Model Provides a Conceptual Basis for the High Antiviral Activity of Major HIV Drugs (2011) (67)
Correction: Association of pol Diversity with Antiretroviral Treatment Outcomes among HIV-Infected African Children (2013) (66)
Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART (2008) (66)
The Enhanced Immune Response to the HIV gp160/LAMP Chimeric Gene Product Targeted to the Lysosome Membrane Protein Trafficking Pathway* (1997) (66)
Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine (1994) (64)
A Human Nuclear Shuttling Protein That Interacts with Human Immunodeficiency Virus Type 1 Matrix Is Packaged into Virions (2000) (63)
Evolution of HIV-1 in an HLA-B*57-positive patient during virologic escape. (2007) (62)
Mechanisms of HIV-1 escape from immune responses and antiretroviral drugs. (2004) (62)
A unique viral reservoir landscape in HIV-1 elite controllers (2020) (61)
Barrier-to-Autointegration Factor BAF Binds p55 Gagand Matrix and Is a Host Component of Human ImmunodeficiencyVirus Type 1Virions (2003) (61)
Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution. (2001) (61)
Different human resting memory CD4+ T cell subsets show similar low inducibility of latent HIV-1 proviruses (2020) (61)
Antigen-driven clonal selection shapes the persistence of HIV-1 infected CD4+ T cells in vivo (2020) (61)
Re-evaluating evolution in the HIV reservoir (2017) (61)
Evidence of CD8+ T-Cell-Mediated Selective Pressure on Human Immunodeficiency Virus Type 1 nef in HLA-B*57+ Elite Suppressors (2008) (60)
Characterization of a conserved T cell epitope in HIV-1 gp41 recognized by vaccine-induced human cytolytic T cells. (1991) (59)
The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors (2008) (59)
Host Factors Dictate Control of Viral Replication in two HIV-1 Controller/Chronic Progressor Transmission Pairs (2012) (59)
Recent developments in the effort to cure HIV infection: going beyond N = 1. (2016) (58)
Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir (2018) (57)
The Landscape of Persistent Viral Genomes in ART-Treated SIV, SHIV, and HIV-2 Infections. (2019) (56)
Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation (2009) (55)
A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy. (2008) (54)
Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity (2017) (53)
Studies of the mechanism of cytolysis by HIV-1-specific CD4+ human CTL clones induced by candidate AIDS vaccines. (1994) (52)
Latency and viral persistence in HIV-1 infection. (2000) (52)
Longitudinal study reveals HIV-1-infected CD4+ T cell dynamics during long-term antiretroviral therapy. (2020) (51)
Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA (2020) (51)
The role of CD4 in HIV envelope-mediated pathogenesis. (1996) (50)
Anchor sequence-dependent endogenous processing of human immunodeficiency virus 1 envelope glycoprotein gp160 for CD4+ T cell recognition (1990) (50)
Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. (2004) (49)
A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes. (1994) (49)
Evaluating Clonal Expansion of HIV-Infected Cells: Optimization of PCR Strategies to Predict Clonality (2016) (49)
DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication. (2005) (49)
Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy (2011) (47)
HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor (1998) (47)
Monitoring Early Fusion Dynamics of Human Immunodeficiency Virus Type 1 at Single-Molecule Resolution (2008) (47)
CMPK2 and BCL-G are associated with type 1 interferon–induced HIV restriction in humans (2018) (46)
Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation (2011) (46)
A primary CD4+ T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescence (2014) (46)
Recent trends in HIV-1 drug resistance. (2013) (45)
The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients (2008) (45)
CD4+ T cells from elite suppressors are more susceptible to HIV-1 but produce fewer virions than cells from chronic progressors (2011) (44)
A novel method for determining the inhibitory potential of anti-HIV drugs. (2009) (44)
Processing of HIV-1 envelope glycoprotein for class I-restricted recognition: dependence on TAP1/2 and mechanisms for cytosolic localization. (1999) (44)
Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution. (2005) (43)
An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes. (1993) (43)
Evolution of the HIV-1 nef gene in HLA-B*57 Positive Elite Suppressors (2010) (42)
HLA-B*57 Elite Suppressor and Chronic Progressor HIV-1 Isolates Replicate Vigorously and Cause CD4+ T Cell Depletion in Humanized BLT Mice (2014) (42)
Insight into treatment of HIV infection from viral dynamics models (2018) (42)
A Novel Assay Allows Genotyping of the Latent Reservoir for Human Immunodeficiency Virus Type 1 in the Resting CD4+ T Cells of Viremic Patients (2005) (42)
Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. (2009) (42)
HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing Assay (2016) (42)
Primary CD8+ T cells from elite suppressors effectively eliminate non-productively HIV-1 infected resting and activated CD4+ T cells (2013) (41)
Corrections: Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 (Proc Natl Acad Sci USA (2014) 111, (13475-13480) doi: 10.1073/pnas.1406663111) (2014) (41)
Pre-steady-state Kinetic Studies Establish Entecavir 5′-Triphosphate as a Substrate for HIV-1 Reverse Transcriptase* (2008) (41)
Novel Pathway for Induction of Latent Virus from Resting CD4+ T Cells in the Simian Immunodeficiency Virus/Macaque Model of Human Immunodeficiency Virus Type 1 Latency (2006) (39)
The latent reservoir for HIV-1 in resting CD4+ T cells and other viral reservoirs during chronic infection: insights from treatment and treatment-interruption trials (2006) (39)
Latency and reservoirs for HIV-1. (1999) (38)
The latent reservoir for HIV-1 in resting CD4+ T cells: a barrier to cure (2006) (37)
A novel cell-based high-throughput screen for inhibitors of HIV-1 gene expression and budding identifies the cardiac glycosides. (2014) (37)
Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir (2009) (37)
Relaxation phenomena in human erythrocyte suspensions. (1976) (36)
The role of CD32 during HIV-1 infection (2018) (36)
Class I-restricted presentation of an HIV-1 gp41 epitope containing an N-linked glycosylation site. Implications for the mechanism of processing of viral envelope proteins. (1996) (35)
Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework. (2010) (35)
Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine. (1993) (35)
Unstimulated Primary CD4+ T Cells from HIV-1-Positive Elite Suppressors Are Fully Susceptible to HIV-1 Entry and Productive Infection (2010) (35)
Cellular immune responses to HIV-1. (1998) (34)
HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation. (1997) (34)
CD8+ T cells from HLA-B*57 elite suppressors effectively suppress replication of HIV-1 escape mutants (2013) (34)
Diverse fates of uracilated HIV-1 DNA during infection of myeloid lineage cells (2016) (33)
MHC class I-restricted processing of transmembrane proteins. Mechanism and biologic significance. (1995) (33)
Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption (2021) (33)
Production of transmembrane and secreted forms of tumor necrosis factor (TNF)-alpha by HIV-1-specific CD4+ cytolytic T lymphocyte clones. Evidence for a TNF-alpha-independent cytolytic mechanism. (1992) (32)
Keeping quiet: microRNAs in HIV-1 latency (2007) (31)
Viral suppression of multiple escape mutants by de novo CD8+ T cell responses in a human immunodeficiency virus-1 Infected elite suppressor (2011) (31)
Reservoir expansion by T-cell proliferation may be another barrier to curing HIV infection (2016) (31)
Genetic variability in HIV-1 gp120 affects interactions with HLA molecules and T cell receptor. (1990) (30)
An Evaluation of Enforced Rapid Proteasomal Degradation as a Means of Enhancing Vaccine-Induced CTL Responses1 (2004) (29)
Unraveling the relationship between microbial translocation and systemic immune activation in HIV infection. (2014) (29)
Suppression of antibody-sensitized tumor cells by macrophages: insufficient supply or activation of macrophages within large tumors. (1979) (28)
Immunization with Th-CTL Fusion Peptide and Cytosine-Phosphate-Guanine DNA in Transgenic HLA-A2 Mice Induces Recognition of HIV-Infected T Cells and Clears Vaccinia Virus Challenge 1 (2003) (28)
Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells. (2014) (28)
Incentives for Viral Suppression in People Living with HIV: A Randomized Clinical Trial (2019) (28)
Mycobacterium tuberculosis Complex Enhances Susceptibility of CD4 T Cells to HIV through a TLR2-Mediated Pathway (2012) (27)
HIV-1-induced depletion of CD4+ T cells in the gut: mechanism and therapeutic implications. (2006) (27)
Assays to Measure Latency, Reservoirs, and Reactivation. (2018) (27)
Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA (2020) (26)
Short communication: dynamic constraints on the second phase compartment of HIV-infected cells. (2011) (26)
Cytokines from vaccine-induced HIV-1 specific cytotoxic T lymphocytes: effects on viral replication. (1993) (26)
New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo (2009) (25)
Major histocompatibility complex independent T cell receptor-antigen interaction: functional analysis using fluorescein derivatives (1991) (25)
Endothelial Cell Stimulation Overcomes Restriction and Promotes Productive and Latent HIV-1 Infection of Resting CD4+ T Cells (2013) (24)
Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1 (2020) (24)
HIV persistence: clonal expansion of cells in the latent reservoir. (2017) (24)
Finding a cure for human immunodeficiency virus-1 infection. (2014) (24)
Characterization of a polyclonal cytolytic T lymphocyte response to human immunodeficiency virus in persons without clinical progression. (1997) (22)
What do we need to do to cure HIV infection. (2010) (22)
Latent reservoirs for HIV-1. (1999) (22)
A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation (2021) (22)
Impact of anti-PD-1 and anti-CTLA-4 on the HIV reservoir in people living with HIV with cancer on antiretroviral therapy: The AIDS Malignancy Consortium-095 study. (2021) (22)
Insufficient Evidence for Rare Activation of Latent HIV in the Absence of Reservoir-Reducing Interventions (2016) (21)
HIV-1 envelope protein is expressed on the surface of infected cells before its processing and presentation to class II-restricted T lymphocytes. (1993) (21)
Recognition of HIV glycoprotein gp120 by T cells. Role of monocyte CD4 in the presentation of gp120. (1989) (20)
Antigen valence determines the binding of nominal antigen to cytolytic T cell clones (1985) (20)
HIV: Not-so-innocent bystanders (2014) (20)
HIV: Early treatment may not be early enough (2014) (20)
Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance. (2015) (20)
Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques (2021) (19)
Preventing AIDS But Not HIV-1 Infection with a DNA Vaccine (2000) (19)
Organization of Cellular Receptors into a Nanoscale Junction during HIV-1 Adhesion (2010) (19)
HSF1 inhibition attenuates HIV-1 latency reversal mediated by several candidate LRAs In Vitro and Ex Vivo (2020) (19)
Opening Fronts in HIV Vaccine Development: Targeting reservoirs to clear and cure (2014) (19)
Studies on the mechanism of lymphocyte-mediated cytolysis. X. Enucleated cells as targets for cytotoxic attack. (1978) (18)
Consistent Inhibition of HIV-1 Replication in CD4+ T Cells by Acyclovir without Detection of Human Herpesviruses (2011) (18)
Preferential Cytolysis of Peripheral Memory CD4+ T Cells by In Vitro X4-Tropic Human Immunodeficiency Virus Type 1 Infection before the Completion of Reverse Transcription (2008) (18)
SIV‐specific T lymphocyte responses in PBMC and lymphoid tissues of SIV‐infected pigtailed macaques during suppressive combination antiretroviral therapy (2005) (17)
Contribution of Virus-Like Particles to the Immunogenicity of Human Immunodeficiency Virus Type 1 Gag-Derived Vaccines in Mice (2005) (17)
Mapping of Specific and Promiscuous HLA-DR-Restricted T-Cell Epitopes on the Plasmodium falciparum 27-Kilodalton Sexual Stage-Specific Antigen (1998) (16)
Quantitative evaluation of the antiretroviral efficacy of dolutegravir. (2016) (16)
Treatment implications of the latent reservoir for HIV-1. (2007) (16)
Cellular immune responses to HIV‐1 in progressive and non‐progressive infections (1996) (16)
Engaging innate immunity in HIV-1 cure strategies (2021) (15)
Elite suppression of HIV-1 replication. (2008) (15)
Rekindled HIV infection (2014) (15)
Reduced Frequency of Cells Latently Infected With Replication-Competent Human Immunodeficiency Virus-1 in Virally Suppressed Individuals Living in Rakai, Uganda (2017) (15)
Low Inducibility of Latent Human Immunodeficiency Virus Type 1 Proviruses as a Major Barrier to Cure. (2021) (15)
An anti-CD45RO immunotoxin kills latently infected human immunodeficiency virus (HIV) CD4 T cells in the blood of HIV-positive persons. (2002) (15)
Complex decay dynamics of HIV virions, intact and defective proviruses, and 2LTR circles following initiation of antiretroviral therapy (2022) (15)
An algorithm for evaluating human cytotoxic T lymphocyte responses to candidate AIDS vaccines. (1999) (15)
Acidic residues in the DRβ chain third hypervariable region are required for stimulation of a DR(α,β1*0402)-restricted T-cell clone (1994) (14)
Medroxyprogesterone acetate increases HIV-1 infection of unstimulated peripheral blood mononuclear cells in vitro (2015) (14)
Adhesion and fusion efficiencies of human immunodeficiency virus type 1 (HIV-1) surface proteins (2013) (14)
In Vivo Dynamics of the Latent Reservoir for HIV-1: New Insights and Implications for Cure. (2021) (14)
Direct evidence for the existence of nominal antigen binding sites on T cell surface Ti alpha-beta heterodimers of MHC-restricted T cell clones. (1986) (13)
Simian-Human Immunodeficiency Virus SHIV.C.CH505 Persistence in ART-Suppressed Infant Macaques Is Characterized by Elevated SHIV RNA in the Gut and a High Abundance of Intact SHIV DNA in Naive CD4+ T Cells (2020) (13)
Biomarkers of HIV replication (2010) (12)
Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection. (2010) (12)
Reservoirs for HIV-1 (1999) (12)
Establishment of latent HIV-1 infection of resting CD4(+) T lymphocytes does not require inactivation of Vpr. (2000) (11)
Residual Plasma Viraemia and Infectious HIV-1 Recovery from Resting Memory CD4 Cells in Patients on Antiretroviral Therapy: Results from ACTG A5173 (2013) (11)
Similar frequency and inducibility of intact HIV-1 proviruses in blood and lymph nodes. (2020) (11)
A Quantitative Measurement of Antiviral Activity of Anti-Human Immunodeficiency Virus Type 1 Drugs against Simian Immunodeficiency Virus Infection: Dose-Response Curve Slope Strongly Influences Class-Specific Inhibitory Potential (2012) (11)
Clonal analysis of T-cell responses to the HIV-1 envelope proteins in AIDS vaccine recipients. (1992) (11)
Loss of HIV-1-specific immunity during treatment interruption in 2 chronically infected patients. (2002) (11)
Measuring reversal of HIV-1 latency ex vivo using cells from infected individuals (2014) (11)
Human immunodeficiency virus. (2009) (11)
Nonsuppressible HIV-1 viremia: a reflection of how the reservoir persists. (2020) (10)
Severe Depletion of CD 4 CD 25 Regulatory T Cells from the Intestinal Lamina Propria but Not Peripheral Blood or Lymph Nodes during Acute Simian Immunodeficiency Virus Infection (2007) (10)
Autologous strain-specific cytolytic T lymphocyte responses directed against human immunodeficiency virus type 1 Env. (1998) (10)
Targeting HIV reservoirs with valproic acid. (2005) (10)
HIV-1 evolution following transmission to an HLA-B*5801-positive patient. (2009) (10)
Measuring the latent reservoir for HIV-1: Quantification bias in near full-length genome sequencing methods (2022) (10)
Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. (2020) (9)
Designing and interpreting limiting dilution assays: general principles and applications to the latent reservoir for HIV-1 (2015) (9)
Increasing extracellular protein concentration reduces intracellular antiretroviral drug concentration and antiviral effect. (2013) (9)
A case of seronegative HIV-1 infection. (2010) (9)
A quantitative approach for measuring the reservoir of latent HIV-1 proviruses (2019) (9)
The diversity of T cell receptors specific for self MHC gene products. (1983) (8)
Association of pol Diversity with Antiretroviral Treatment Outcomes among HIV-Infected African Children (2013) (8)
Taking aim at HIV replication (2000) (8)
Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine. (1994) (8)
H-2 restriction: independent recognition of H-2 and foreign antigen by a single receptor. (1980) (7)
Dual zinc-finger nucleases block HIV infection. (2014) (7)
Cross-reactive microbial peptides can modulate HIV-specific CD8+ T cell responses (2018) (7)
Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs (2010) (6)
Interleukin 2 treatment for HIV infection. (2000) (6)
Immune alteration fends off AIDS (2008) (6)
The Effect of early treatment on the latent reservoir of HIV-1. (2005) (6)
Chloramphenicol metabolism in isolated rat hepatocytes. (1978) (6)
Crosscurrents in HIV-1 evolution (2006) (6)
Stoichiometric parameters of HIV-1 entry. (2015) (6)
Can antiretroviral therapy ever be stopped? (2000) (6)
CD4+ T cell epitopes in HIV-1 proteins. (1993) (5)
MHC class II genotype and the control of viremia in HIV-1-infected individuals on highly active antiretroviral therapy. (2001) (5)
8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
Acidic residues in the DR beta chain third hypervariable region are required for stimulation of a DR(alpha, beta 1*0402)-restricted T-cell clone. (1994) (5)
Multiple genetic programs contribute to CD4 T cell memory differentiation and longevity by maintaining T cell quiescence (2020) (5)
Clonally expanded HIV-1 proviruses with 5′-leader defects can give rise to nonsuppressible residual viremia (2023) (4)
Non-structured treatment interruptions are associated with higher HIV reservoir size measured by intact proviral DNA assay in people who inject drugs. (2020) (4)
The ins and outs of HIV endocytosis. (1997) (4)
Human T lymphocyte activation. (1987) (4)
A reservoir for HIV in patients on combination antiretroviral therapy. (1998) (3)
Intact proviral DNA levels decline in people with HIV on antiretroviral therapy (2019) (3)
Faculty Opinions recommendation of Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. (2012) (3)
Chapter 11 – Immunodeficiency in HIV-1 Infection (2004) (3)
Majority of the latent reservoir resides in CD32a negative CD4+ T cells (2017) (2)
A-101 Defective proviruses rapidly accumulate during acute HIV-1 infection (2017) (2)
Achieving a quantitative understanding of antiretroviral drug efficacy. (2010) (2)
Can antiretroviral therapy ever be stopped? An update. (2004) (2)
The binding of nominal antigen to T cell clones (1985) (2)
Human immunodeficiency virus glycoprotein-specific CD4+ cytotoxic T lymphocytes are involved in two types of cytotoxicity: antigen-specific and cell-cell fusion-related cell lysis. (1997) (2)
Acquired immune deficiency syndrome (AIDS). (2006) (2)
REPLICATION-COMPETENT NON-INDUCED PROVIRUSES IN THE LATENT RESERVOIR INCREASE BARRIER TO HIV-1 CURE by Ya-Chi Ho A dissertation submitted to the Johns Hopkins University School of Medicine in conformity with the requirements for the degree of Doctor of Philosophy (2013) (2)
Contribution of antigenic exposure to the persistence of HIV-infected CD4 T cells in vivo (2019) (2)
A lymphokine that activates the cytolytic program of both cytotoxic T lymphocyte and natural killer clones [retracted by Reinherz EL. In: J Exp Med 1987 Jan 1;165(1):275] (1986) (2)
Constructing Mobius Transformations with Spheres (2017) (2)
Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques (2022) (2)
Perturbations in the CD4+CD25+ regulatory T cell population of the GALT during acute SIV infection (2006) (2)
Erratum: Nuclear landscape of HIV-1 infection and integration (2017) (2)
Making sense of HIV innate sensing. (2013) (2)
HIV Prevention and Treatment Fields Join Forces (2014) (2)
Psychological Distress and Physical Pain Appear To Have No Short-Term Adverse Impact on Plasma HIV-1 RNA Levels in Patients on Successful HAART (2005) (2)
Erratum: Marked intraindividual variability in antiretrovrial concentrations may limit the utility of therapeutic drug monitoring (Clinical Infectious Diseases (April 15, 2006) 42 (1189-1196)) (2006) (1)
Genome editing for clinical HIV isolates (2016) (1)
CD8+T cells from HLA-B*57 elite suppressors effectively suppress replication of HIV-1 escape mutants (2013) (1)
Genome-wide CRISPR screens identify combinations of candidate latency reversing agents for targeting the latent HIV-1 reservoir (2022) (1)
Brief Definitive Report a Lymphokine That Activates the Cytolytic Program of Both Cytotoxic T Lymphocyte and Natural Killer Clones (2003) (1)
Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques (2022) (1)
Structured therapeutic interruptions: a review. (2001) (1)
HIV replication and evolution in patients on highly active antiretroviral therapy (2006) (1)
Clears Vaccinia Virus Challenge Recognition of HIV-Infected T Cells and Transgenic HLA-A 2 Mice Induces and Cytosine-Phosphate-Guanine DNA in Immunization with Th-CTL Fusion Peptide (2003) (1)
TCR-mimic bispecific antibodies to target the HIV-1 reservoir (2022) (1)
Early treatment may not be early enough Giving monkeys antiretroviral therapy from just three days after exposure to simian immunodeficiency virus does not prevent a subsequent rebound of viral replication, suggesting that viral reservoirs are established early. (2014) (1)
A Cell-Free Antigen Processing System Reveals Factors Critical for HIV-1 Epitope Dominance and Informs Vaccine Design (2021) (1)
Primary CD8+ T cells from elite suppressors effectively eliminate non-productively HIV-1 infected resting and activated CD4+T cells (2013) (1)
T-Cell Epitopes of HIV-1 Envelope Glycoprotein (1996) (1)
Viral Dynamics in HIV-1 Infection Review (1998) (1)
Using highly active antiretroviral therapy to decrease perioperative HIV-1 transmission risk. (2010) (1)
HIV latency and integration site placement in five cell-based models (2013) (1)
Measurement of antiviral activity in drugs for HIV-1. (2011) (1)
Use of TCR-mimic bispecific antibodies against pMHC-II for monitoring antigen processing and redirecting cytolytic effector cells (2020) (1)
Shared Mechanisms Govern HIV Transcriptional Suppression in Circulating CD103+ and Gut CD4+ T Cells (2020) (1)
Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV (2016) (1)
Recognition Of Hiv-1-infected Cells By Cd4: Analysis Of Antigen Processing Mechanisms T Cells: Analysis Of Antigen Processing Mechanisms (1993) (0)
Preservation of FoxP3 (cid:1) Regulatory T Cells in the Peripheral Blood of Human Immunodeﬁciency Virus Type 1-Infected Elite Suppressors Correlates with Low CD4 (cid:1) T-Cell Activation (cid:1) (2008) (0)
TruncationofKir 6 . 2 produces ATP-sensitiveK þ channels in theabsenceof the sulphonylurea receptor (1997) (0)
PP 4.8 – 00108 Presentation of cognate antigens by dendritic cells causes stochastic HIV expression (2022) (0)
Cytosolic Localization Dependence on TAP1/2 and Mechanisms for for Class I-Restricted Recognition: Processing of HIV-1 Envelope Glycoprotein (1999) (0)
Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir (2018) (0)
Activation of Precursor and Mature T Lymphocytes via the 50KD T11 Molecule (1986) (0)
H-2restriction: Independent recognition ofH-2andforeign antigen byasingle receptor (cytotoxic Tcell/major histocompatibility complex/immune response gene) (1980) (0)
News in brief (1968) (0)
A cell-free antigen processing system informs HIV-1 epitope selection and vaccine design. (2023) (0)
Abstracts of the 9th HIV Persistence During Therapy Workshop (2019) (0)
HIV in the Lymph Tissue and Latent Long-lasting Virus in T Cells ( CD 4 s ) by Dr . (1998) (0)
Lin Shen Antiviral Activity of Major HIV Drugs A Critical Subset Model Provides a Conceptual Basis for the High (2011) (0)
Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV (2017) (0)
Newly Uncovered Viral Reservoir Latent Long-lasting Proviral DNA Protease Inhibitor Update Treatment Options After Failing a Protease Inhibitor Monthly Monitoring of Viral Load Commentary (1998) (0)
Heightened resistance to type 1 interferons characterizes HIV-1 at transmission and following analytical treatment interruption (2020) (0)
HIV rebound and meningoencephalitis following ART interruption after allogeneic hematopoietic stem cell transplant: an investigation of the source of HIV rebound (2015) (0)
Method for triggering cytotoxicity. (1987) (0)
Enhancing Vaccine-Induced CTL Responses Proteasomal Degradation as a Means of An Evaluation of Enforced Rapid (2004) (0)
Different Routes Following Exposure to Vaccinia Virus Via CTL + Differentially to the Induction of CD 8 Direct Priming and Cross-Priming Contribute (2002) (0)
Estimating reservoir size with uncertainty in viral dynamics parameters (2016) (0)
This information is current as Subsets in SIV-Infected Macaques or IL-15 Induces Distinct CD8 Memory Immunodeficiency Virus (SIV)-DNA+IL-12 Therapeutic Vaccination with Simian (2013) (0)
Distinct viral reservoirs in individuals with spontaneous control of HIV-1 (2020) (0)
B-103 Update on IHV Cure Research (2014) (0)
Current HIV/SIV Reservoir Assays for Preclinical and Clinical Applications: Recommendations from the Experts 2022 NIAID Workshop Summary. (2023) (0)
Allogeneic Bone Marrow Transplant for HIV Patients with Hematologic Malignancies with Post-transplant Cyclophosphamide: a Feasibility Study (2020) (0)
Author response: Diverse fates of uracilated HIV-1 DNA during infection of myeloid lineage cells (2016) (0)
Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques (2022) (0)
CMV-specific T cells Attenuated poxviruses generate clinically relevant frequencies of (2013) (0)
Recommendations for measuring HIV reservoir size in cure-directed clinical trials (2020) (0)
Viral reservoirs, latency and mechanisms of HIV persistence (2007) (0)
OA1-1 Impact of vorinostat treatment of non-Hodgkin‘s lymphoma on HIV-1 latent reservoir (2017) (0)
Effect of Acyclovir on HIV-1 Set Point among HSV-2 Seropositive Persons during Early HIV-1 Infection (2010) (0)
Editorial: JQ1: giving HIV‐1 expression a boost by blocking bromodomains? (2012) (0)
Quantifying combination ARV drug effects in wild type and resistant HIV-1 infection (2012) (0)
Analyzing the unperturbed HIV-1 T cell reservoir. (2023) (0)
The effect of induction immunosuppression for kidney transplant on the latent HIV reservoir (2022) (0)
A new de novo approach for optimizing peptides that inhibit HIV-1 entry (2007) (0)
Unstimulated Primary CD4 (cid:1) T Cells from HIV-1-Positive Elite Suppressors Are Fully Susceptible to HIV-1 Entry and Productive Infection (cid:1) (2010) (0)
Quantitative Analysis of Latently Infected Resting CD4+ T Lymphocytes in Children with Perinatally Acquired Human Immunodeficiency Virus Type-1 Infection ♦ 888 (1998) (0)
Tooth structure re-engineered Mice deficient in the EDA protein lack normal tooth features. Restoring EDA in embryonic teeth at increasing doses has now been found to recover these dental features in a stepwise pattern that mimics evolution. See Article p.44 (2014) (0)
Antigenby N-End Rule Targeting of a Model Tumor Vivo CTL-Dependent Protective Immunity In Cutting Edge: Induction of Enhanced (1998) (0)
Contributors (2012) (0)
Correction: Association of pol Diversity with Antiretroviral Treatment Outcomes among HIV-Infected African Children (2013) (0)
The latent reservoir as a barrier to cure (2016) (0)
Assessing non-classical antigen presentation in HIV-infected CD4+ T cells. (2018) (0)
101 Understanding How HAART Works (2012) (0)
393 – Immunopathogenesis of Human Immunodeficiency Virus Infection (2011) (0)
Antibody Diversification Impacts Retroviral Restriction and AID / APOBEC Family Differentially Local Sequence Targeting in the Enzymology (2010) (0)
Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy (2019) (0)
B-101 Unique features of effector to memory transition render CD4+ T cells permissive for latent HIV infection (2016) (0)
Faculty Opinions recommendation of Dominance of the CD4(+) T helper cell response during acute resolving hepatitis A virus infection. (2012) (0)
Molecular Aspects of Human B and T Lymphocyte Responses to HIV (1990) (0)
Safety of optimized antiretroviral therapy during allogeneic matched and haploidentical bone marrow transplant in HIV+ individuals (2015) (0)
Reply: To PMID 25117799. (2015) (0)
Severe Depletion of CD4 (cid:1) CD25 (cid:1) Regulatory T Cells from the Intestinal Lamina Propria but Not Peripheral Blood or Lymph Nodes during Acute Simian Immunodeﬁciency Virus Infection (cid:1) (2007) (0)
Comment on Didigu et al , page 61 Dual zinc-finger nucleases block HIV infection (0)
A Novel Post-transcriptional Block in Gene Expression Contributes to HIV-1 Latency In Vivo (2005) (0)
NATAP FORUM Current Issues in HIV Treatment: NATAP's Fifth Continuing Education Symposium (1998) (0)

This paper list is powered by the following services:

Other Resources About Robert F. Siliciano

en.wikipedia.org

What Schools Are Affiliated With Robert F. Siliciano?

Robert F. Siliciano is affiliated with the following schools:

Robert F. Siliciano's Academic­Influence.com Rankings

Robert F. Siliciano's Degrees

Why Is Robert F. Siliciano Influential?

Robert F. Siliciano's Published Works

Published Works

Other Resources About Robert F. Siliciano

What Schools Are Affiliated With Robert F. Siliciano?

Robert F. Siliciano's AcademicInfluence.com Rankings